Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study

Respiratory Medicine

Volumn 147, Issue , 2019, Pages 37-43

  Papi, Alberto ^a   Zheng, Jinping ^b   Criner, Gerard J ^c   Fabbri, Leonardo M ^a,d   Calverley, Peter M A ^e  

^a UNIVERSITY OF FERRARA   (Italy)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Exacerbations; Mucolytic

Indexed keywords

ACETYLCYSTEINE; BRONCHODILATING AGENT; CORTICOSTEROID; PLACEBO; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; EXPECTORANT AGENT;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEALTH CARE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PRIORITY JOURNAL; RISK REDUCTION; SMOKING; SYMPTOM; ADVERSE EVENT; CHINA; COMPARATIVE STUDY; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX;

ACETYLCYSTEINE; ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; BRONCHODILATOR AGENTS; CHINA; DISEASE PROGRESSION; EXPECTORANTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SMOKING;

EID: 85059866181     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2018.12.014     Document Type: Article

References (29)

1. Global Initiative for Chronic Obstructive Lung Disease, Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2019 www.goldcopd.org. (Accessed 10 January 2019)
2. Andersson, F., Borg, S., Jansson, S.A., Jonsson, A.C., Ericsson, A., Prütz, C., Rönmark, E., Lundbäck, B., The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir. Med. 96 (2002), 700–708.
3. Dhamane, A., Moretz, C., Zhou, Y., Burslem, K., Saverno, K., Jain, G., Renda, A.M., Kaila, S., COPD exacerbation frequency and its association with health care resource utilization and costs. Int. J. Chronic Obstr. Pulm. Dis. 10 (2015), 2609–2618, 10.2147/COPD.S90148.
4. Thomas, M., Radwan, A., Stonham, C., Marshall, S., COPD exacerbation frequency, pharmacotherapy and resource use: an observational study in UK primary care. COPD 11 (2014), 300–309, 10.3109/15412555.2013.841671.
5. Punekar, Y.S., Shukla, A., Müllerova, H., COPD management costs according to the frequency of COPD exacerbations in UK primary care. Int. J. Chronic Obstr. Pulm. Dis. 9 (2014), 65–73, 10.2147/COPD.S54417.
6. Cazzola, M., Calzetta, L., Page, C., Jardim, J., Chuchalin, A.G., Rogliani, P., Gabriella Matera, M., Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur. Respir. Rev. 24 (2015), 451–461, 10.1183/16000617.00002215.
7. Tse, H.N., Raiteri, L., Wong, K.Y., Yee, K.S., Ng, L.Y., Wai, K.Y., Loo, C.K., Chan, M.H., High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest 144 (2013), 106–118, 10.1378/chest.12-2357.
8. Zheng, J.-P., Wen, F.-Q., Bai, C.-X., Wan, H.-Y., Kang, J., Chen, P., Yao, W.-Z., Ma, L.-J., Li, X., Raiteri, L., Sardina, M., Gao, Y., Wang, B.-S., Zhong, N.-S., Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir. Med. 2 (2014), 187–194, 10.1016/S2213-2600(13)70286-8.
9. Anthonisen, N.R., Manfreda, J., Warren, C.P., Hershfield, E.S., Harding, G.K., Nelson, N.A., Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 106 (1987), 196–204, 10.7326/0003-4819-106-2-196.
10. Decramer, M., Rutten-van Mölken, M., Dekhuijzen, P.N.R., Troosters, T., van Herwaarden, C., Pellegrino, R., van Schayck, C.P.O., Olivieri, D., Del Donno, M., De Backer, W., Lankhorst, I., Ardia, A., Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 365 (2005), 1552–1560, 10.1016/S0140-6736(05)66456-2.
11. Zheng, J.-P., Wen, F.-Q., Bai, C.-X., Wan, H.-Y., Kang, J., Chen, P., Yao, W.-Z., Ma, L.-J., Xia, Q., Gao, Y., Zhong, N.-S., High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study. COPD 10 (2013), 164–171, 10.3109/15412555.2012.732628.
12. Aaron, S.D., Vandemheen, K.L., Fergusson, D., Maltais, F., Bourbeau, J., Goldstein, R., Balter, M., O'Donnell, D., McIvor, A., Sharma, S., Bishop, G., Anthony, J., Cowie, R., Field, S., Hirsch, A., Hernandez, P., Rivington, R., Road, J., Hoffstein, V., Hodder, R., Marciniuk, D., McCormack, D., Fox, G., Cox, G., Prins, H.B., Ford, G., Bleskie, D., Doucette, S., Mayers, I., Chapman, K., Zamel, N., FitzGerald, M., C.T.S.R.C.R. Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 146 (2007), 545–555, 10.7326/0003-4819-146-8-200704170-00152.
13. Martinez, F.J., Calverley, P.M.A., Goehring, U.-M., Brose, M., Fabbri, L.M., Rabe, K.F., Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 385 (2015), 857–866, 10.1016/S0140-6736(14)62410-7.
14. Albert, R.K., Connett, J., Bailey, W.C., Casaburi, R., Cooper, J.A.D., Criner, G.J., Curtis, J.L., Dransfield, M.T., Han, M.K., Lazarus, S.C., Make, B., Marchetti, N., Martinez, F.J., Madinger, N.E., McEvoy, C., Niewoehner, D.E., Porsasz, J., Price, C.S., Reilly, J., Scanlon, P.D., Sciurba, F.C., Scharf, S.M., Washko, G.R., Woodruff, P.G., Anthonisen, N.R., COPD clinical research network, azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 365 (2011), 689–698, 10.1056/NEJMoa1104623.
15. Tashkin, D.P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., Decramer, M., Investigators, U.S., A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 359 (2008), 1543–1554, 10.1056/NEJMoa0805800.
16. Calverley, P.M.A., Anderson, J.A., Celli, B., Ferguson, G.T., Jenkins, C., Jones, P.W., Yates, J.C., Vestbo, J., On behalf of the TORCH Investigators, Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356 (2007), 775–789, 10.1056/NEJMoa063070.
17. Lipson, D.A., Barnacle, H., Birk, R., Brealey, N., Locantore, N., Lomas, D.A., Ludwig-Sengpiel, A., Mohindra, R., Tabberer, M., Zhu, C.-Q., Pascoe, S.J., FULFIL Trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 196 (2017), 438–446, 10.1164/rccm.201703-0449OC.
18. Singh, D., Papi, A., Corradi, M., Pavlišová I., Montagna, I., Francisco, C., Cohuet, G., Vezzoli, S., Scuri, M., Vestbo, J., Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 388 (2016), 963–973, 10.1016/S0140-6736(16)31354-X.
19. Vestbo, J., Papi, A., Corradi, M., Blazhko, V., Montagna, I., Francisco, C., Cohuet, G., Vezzoli, S., Scuri, M., Singh, D., Single inhaler extra fine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet 389 (2017), 1919–1929, 10.1016/S0140-6736(17)30188-5.
20. Papi, A., Vestbo, J., Fabbri, L., Corradi, M., Prunier, H., Cohuet, G., Guasconi, A., Montagna, I., Vezzoli, S., Petruzzelli, S., Scuri, M., Roche, N., Singh, D., Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 391 (2018), 1076–1084, 10.1016/S0140-6736(18)30206-X.
21. Lipson, D.A., Barnhart, F., Brealey, N., Brooks, J., Criner, G.J., Day, N.C., Dransfield, M.T., Halpin, D.M.G., Han, M.K., Jones, C.E., Kilbride, S., Lange, P., Lomas, D.A., Martinez, F.J., Singh, D., Tabberer, M., Wise, R.A., Pascoe, S.J., For the IMPACT investigators, Once-daily single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 378 (2018), 1671–1680, 10.1056/NEJMoa1713901.
22. Ferguson, G.T., Rabe, K.F., Martinez, F.J., Fabbri, L.M., Wang, C., Ichinose, M., Bourne, E., Ballal, S., Darken, P., DeAngelis, K., Aurivillius, M., Dorinsky, P.M., Reisner, C., Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, ph 3 randomised controlled trial. Lancet Respir. Med. 6 (2018), 747–758, 10.1016/S2213-2600(18)30327-8.
23. Carraro, S., Scheltema, N., Bont, L., Baraldi, E., Early-life origins of chronic respiratory diseases: understanding and promoting healthy ageing. Eur. Respir. J. 44 (2014), 1682–1696, 10.1183/09031936.00084114.
24. Miele, C.H., Jaganath, D., Miranda, J.J., Bernabe-Ortiz, A., Gilman, R.H., Johnson, C.M., Diette, G.B., Wise, R.A., Checkley, W., CRONICAS Cohort Study Group, Urbanization and daily exposure to biomass fuel smoke both contribute to chronic bronchitis risk in a population with low prevalence of daily tobacco smoking. COPD 13 (2016), 186–195, 10.3109/15412555.2015.1067765.
25. Grigsby, M., Siddharthan, T., Chowdhury, M.A., Siddiquee, A., Rubinstein, A., Sobrino, E., Miranda, J.J., Bernabe-Ortiz, A., Alam, D., Checkley, W., Socioeconomic status and COPD among low- and middle-income countries. Int. J. Chronic Obstr. Pulm. Dis. 11 (2016), 2497–2507, 10.2147/COPD.S111145.
26. Salvi, S.S., Barnes, P.J., Chronic obstructive pulmonary disease in non-smokers. Lancet 374 (2009), 733–743, 10.1016/S0140-6736(09)61303-9.
27. Jones, P.W., Beeh, K.M., Chapman, K.R., Decramer, M., Mahler, D.A., Wedzicha, J.A., Minimal clinically important differences in pharmacological trials. Am. J. Respir. Crit. Care Med. 189 (2014), 250–255, 10.1164/rccm.201310-1863PP.
28. Chapman, K.R., Bergeron, C., Bhutani, M., Bourbeau, J., Grossman, R.F., Hernandez, P., McIvor, R.A., Mayers, I., Do we know the minimal clinically important difference (MCID) for COPD exacerbations?. COPD 10 (2013), 243–249, 10.3109/15412555.2012.733463.
29. Yang, I.A., Clarke, M.S., Sim, E.H.A., Fong, K.M., Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.(7), 2012, CD002991, 10.1002/14651858.CD002991.pub3.